Santen
Text Size
Listen
Santen Global
  • Patients
  • Healthcare Professionals
  • Careers
  • Investors
Listen

Tap on the left to use.

  • Who We Are
    Message
    Message from the CEO
    CORE PRINCIPLE / WORLD VISION
    CORE PRINCIPLE / WORLD VISION
    VALUES
    VALUES
    History
    History of Santen
    Corporate Executives
    Top Management
    Corporate Executive
    Corporate Governance
    Corporate Governance
    Policies
    Policies and Statements
    Company Infomation
    Overview / Map
    Global Operation
  • What We Do
    Santen 2030
    Santen 2030
    Medium-term Management Plan
    Efforts to Enhance Patients' Satisfaction
    Efforts to Enhance Product Safety
    Efforts to Enhance Product Usability
    Efforts to Address Untreated Patients
    Research & Development
    Research & Development
    The Ophthalmic Product Process: R&D
    Partnering
    Santen's Partnership
    Our Partners
    Partnering Contact
    Production
    Production
    Quality Compliance
    The Ophthalmic Production Process: Production
    Sales & Marketing
    Sales & Marketing
  • Our Stories
  • Sustainability
    Sustainability at Santen
    Sustainability at Santen
    Social
    Access to Healthcare
    Research & Development in Ophthalmology
    Product Quality & Safety
    Supply Chain
    Human Rights
    Talent
    Digital Transformation (DX)
    Governance
    Corporate Governance
    Compliance
    Ethical Marketing
    Risk Management
    Environment​
    Measures against Climate Change
    Environmental Load Reduction
    Disclosures Based on the TCFD Recommendations
    Inclusion
    Inclusive Society Santen Promotes
    Santen Initiatives
    Santen Activities for Inclusive Society
    Related Information
    Participating in the UN Global Compact
    Social Contribution Activities
    Stakeholder Engagement
    Environmental Data 2022
    Employment and Human Resources Data 2022
    GRI Standards Content Index
    Sustainability Library
    External Assessment
  • News
    News
    Show All
    Press Release
    IR News
    Information
  1. HOME
  2. News
  3. 2012

2012 News

  • Press Release
  • IR News
  • Information

Press Release

12.17.2012 Changes in Significant Shareholders
11.27.2012 Santen Files for Manufacturing/Marketing Approval of its Anti-Allergic Ophthalmic Solution DE-114 (Generic name: Epinastine Hydrochloride)
11.27.2012 Intravitreal VEGF Inhibitor "EYLEA (aflibercept) Solution for Intravitreal Injection" Released on the Market for the Treatment of Wet Age-Related Macular Degeneration
11.01.2012 Notice of Cancellation of Treasury Shares
10.03.2012 Santen to Renew the Sante 40 OTC Eye Drop Series
Press Release

IR News

12.17.2012 Changes in Significant Shareholders
11.27.2012 Santen Files for Manufacturing/Marketing Approval of its Anti-Allergic Ophthalmic Solution DE-114 (Generic name: Epinastine Hydrochloride)
11.27.2012 Intravitreal VEGF Inhibitor "EYLEA (aflibercept) Solution for Intravitreal Injection" Released on the Market for the Treatment of Wet Age-Related Macular Degeneration
11.01.2012 Notice of Cancellation of Treasury Shares
10.03.2012 Santen to Renew the Sante 40 OTC Eye Drop Series
IR News

Information

Information
News Archive

Official SNS

Twitter LinkedIn YouTube
  • Accessibility
  • Terms of Use
  • Privacy Policy
  • Contact
Copyright © 2023 Santen Pharmaceutical Co., Ltd.
All Rights Reserved